Figure S4 from A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma

Key Points

• Combination therapy with RAS inhibitors and CDK4/6 inhibitors leads to long-term tumor control in pancreatic ductal adenocarcinoma.
• Immune infiltrates in tumors indicate a shift towards immune equilibrium following treatment.
• The study characterizes the immune dependency of anti-tumor activity, emphasizing its significance.
• Findings point to the critical role of senescence in promoting effective immune responses against tumors.